The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sarcoma Oncology Center
Leadership - Sarcoma Oncology Center
Stock and Other Ownership Interests - AADi
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
 
Sant P. Chawla
No Relationships to Disclose
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Katherine Kim
No Relationships to Disclose
 
Nupur Assudani
No Relationships to Disclose
 
Ahmad Al-Shihabi
No Relationships to Disclose
 
Ania Moradkhani
No Relationships to Disclose
 
Doris Quon
No Relationships to Disclose
 
Steven Wong
No Relationships to Disclose
 
William W. Tseng
No Relationships to Disclose
 
Seth Pollack
No Relationships to Disclose
 
Amor M. Srikureja
No Relationships to Disclose
 
John Jalas
No Relationships to Disclose
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Deciphera; Eisai; Immodulon Therapeutics; Immune Design; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Erlinda Maria Gordon
Research Funding - Bristol-Myers Squibb